Saturday 17 October 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS fell 352.7%, free cash flow fell 67.9% and total debt rose 2,468.3%, each against the same quarter a year earlier.
4.04
0.35
−7.97%
Follow APUS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.51 | 0.90 | 1.31 | 8.34 |
+7 more quarters Free account |
Net Debt/EBITDA |
(0.10) | 0.21 | 0.65 | 3.79 | |
Debt/Assets |
6.98% | 5.62% | 4.32% | 0.00% | |
Debt/Equity |
0.08 | 0.06 | 0.05 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | 0.06 | 3.30 | 0.97 | |
Capex/Depreciation |
0.00 | (0.47) | (5.35) | (15.00) | |
Interest Coverage |
(1.95) | (14.18) | (32.65) | (292.73) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.91 | 0.91 | 0.91 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(3.31) | (1.34) | (3.53) | (1.39) | |
Cash per Share |
4.83 | 6.76 | 10.69 | 5.56 | |
Shareholders Equity per Share |
62.14 | 81.55 | 140.92 | 6.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
62.14 | 81.55 | 140.92 | 6.49 | |
Free Cash Flow |
(5.67) | (2.08) | (3.84) | (1.75) | |
Working Capital |
(10.39) | (1.43) | 3.28 | 8.00 | |
Capital Expenditures |
0.00 | (0.01) | (0.02) | (0.02) | |
Net Current Asset Value |
(10.50) | (1.55) | 3.15 | 8.00 | |
| Other line items | |||||
Quick Ratio |
0.39 | 0.72 | 1.09 | 6.41 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.31) | (1.33) | (3.51) | (1.37) | |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.02) | |
Average Payables |
1.67 | 1.96 | 0.75 | 0.31 | |
Average Assets |
69.09 | 70.74 | 82.10 | 4.84 | |
Average Common Equity |
58.09 | 62.34 | 75.99 | 4.10 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates